See more : Chd Chemicals Limited (CHDCHEM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Pressure BioSciences, Inc. (PBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pressure BioSciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- 360 Capital Group Limited (TGP.AX) Income Statement Analysis – Financial Results
- Walkabout Resources Limited (WKT.AX) Income Statement Analysis – Financial Results
- SEPC Limited (SHRIRAMEPC.NS) Income Statement Analysis – Financial Results
- Yamaguchi Financial Group, Inc. (YFGSF) Income Statement Analysis – Financial Results
- Kodiak Copper Corp. (KDKCF) Income Statement Analysis – Financial Results
Pressure BioSciences, Inc. (PBIO)
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.98M | 1.73M | 2.00M | 1.22M | 1.81M | 2.46M | 2.24M | 1.98M | 1.80M | 1.37M | 1.50M | 1.24M | 987.73K | 1.34M | 1.24M | 852.26K | 645.87K | 210.29K | 105.53K | 412.62K | 23.30M | 22.76M | 21.83M | 19.47M | 29.30M | 26.10M | 22.30M | 15.50M |
| Cost of Revenue | 1.18M | 2.01M | 942.38K | 582.85K | 1.20M | 1.28M | 1.27M | 834.01K | 609.05K | 652.44K | 567.83K | 416.42K | 342.87K | 376.51K | 402.34K | 401.02K | 209.05K | 165.23K | 177.35K | 572.32K | 14.87M | 14.26M | 13.12M | 11.24M | 16.90M | 14.80M | 12.10M | 8.60M |
| Gross Profit | 799.56K | -284.66K | 1.06M | 637.74K | 612.93K | 1.18M | 967.14K | 1.14M | 1.19M | 722.31K | 935.46K | 821.80K | 644.86K | 963.52K | 842.57K | 451.25K | 436.82K | 45.06K | -71.82K | -159.71K | 8.43M | 8.50M | 8.71M | 8.23M | 12.40M | 11.30M | 10.20M | 6.90M |
| Gross Profit Ratio | 40.43% | -16.46% | 52.94% | 52.25% | 33.86% | 47.91% | 43.17% | 57.80% | 66.12% | 52.54% | 62.23% | 66.37% | 65.29% | 71.90% | 67.68% | 52.95% | 67.63% | 21.43% | -68.06% | -38.71% | 36.19% | 37.35% | 39.88% | 42.26% | 42.32% | 43.30% | 45.74% | 44.52% |
| Research & Development | 1.37M | 969.53K | 1.10M | 1.14M | 1.16M | 1.21M | 988.60K | 1.18M | 1.11M | 952.56K | 1.04M | 965.62K | 969.47K | 1.23M | 1.18M | 1.81M | 2.02M | 1.43M | 498.58K | 419.94K | 1.82M | 2.61M | 2.30M | 2.44M | 3.30M | 2.50M | 1.30M | 0.00 |
| General & Administrative | 8.21M | 3.24M | 3.82M | 3.43M | 4.58M | 3.44M | 3.42M | 2.82M | 2.90M | 2.39M | 2.47M | 2.61M | 2.03M | 1.92M | 1.81M | 1.92M | 2.17M | 0.00 | 0.00 | 0.00 | 4.35B | 4.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 730.71K | 401.44K | 324.73K | 649.78K | 680.63K | 1.01M | 1.21M | 872.37K | 745.57K | 721.23K | 752.29K | 714.64K | 931.07K | 1.20M | 1.05M | 1.69M | 1.39M | 0.00 | 0.00 | 0.00 | 3.28B | 3.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.94M | 3.64M | 4.14M | 4.08M | 5.26M | 4.45M | 4.63M | 3.70M | 3.65M | 3.11M | 3.23M | 3.32M | 2.97M | 3.13M | 2.86M | 3.61M | 3.56M | 2.67M | 1.85M | 1.81M | 7.63M | 7.39M | 6.89M | 7.58M | 8.40M | 8.20M | 6.60M | 5.40M |
| Other Expenses | 0.00 | 7.85K | 0.00 | 0.00 | 4.02K | -1.31M | -192.48K | -1.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 | 0.00 | 0.00 | 1.61M | 1.60M | 1.30M | 900.00K | 600.00K |
| Operating Expenses | 10.30M | 4.61M | 5.25M | 5.22M | 6.42M | 5.65M | 5.61M | 4.88M | 4.75M | 4.06M | 4.26M | 4.29M | 3.94M | 4.36M | 4.04M | 5.42M | 5.58M | 4.10M | 2.35M | 2.22M | 9.44M | 10.01M | 9.20M | 11.63M | 13.30M | 12.00M | 8.80M | 6.00M |
| Cost & Expenses | 11.48M | 6.63M | 6.19M | 5.81M | 7.62M | 6.93M | 6.89M | 5.71M | 5.36M | 4.71M | 4.83M | 4.70M | 4.28M | 4.74M | 4.44M | 5.82M | 5.79M | 4.27M | 2.52M | 2.79M | 24.31M | 24.27M | 22.32M | 22.87M | 30.20M | 26.80M | 20.90M | 14.60M |
| Interest Income | 0.00 | 10.44M | 14.45M | 8.34M | 5.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.30K | 4.99K | 57.95K | 286.60K | 0.00 | 0.00 | 0.00 | 19.39M | 41.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.58M | 10.44M | 14.45M | 8.34M | 5.28M | 4.17M | 6.06M | 4.50M | 4.15M | 1.30M | 339.82K | 133.42K | 136.60K | 2.30K | 4.99K | 57.95K | 0.00 | 0.00 | 0.00 | 0.00 | 291.28K | 247.97K | 438.01K | 1.62M | 0.00 | 100.00K | 0.00 | 200.00K |
| Depreciation & Amortization | 112.45K | 233.26K | 175.32K | 203.89K | 183.40K | 94.27K | 8.58K | 17.94K | 25.29K | 65.71K | 79.56K | 107.52K | 141.32K | 197.43K | 204.34K | 200.00K | 179.45K | 146.26K | 106.55K | 146.27K | 1.25M | 1.30M | 1.42M | 1.61M | 1.60M | 1.30M | 900.00K | 600.00K |
| EBITDA | -9.39M | -5.40M | -5.53M | -7.46M | -6.41M | -5.44M | -4.65M | -3.72M | -3.24M | -3.24M | -3.67M | -3.36M | -2.72M | -2.95M | -2.99M | -4.71M | -5.15M | -3.91M | -2.42M | -2.25M | -1.19M | -201.80K | 924.66K | -1.79M | -111.76K | 344.11K | 2.30M | 1.50M |
| EBITDA Ratio | -474.82% | -275.86% | -203.51% | -365.27% | -313.70% | -231.80% | -215.62% | -188.15% | -196.91% | -238.05% | -188.27% | -282.74% | -318.79% | -257.14% | -240.36% | -559.26% | -1,083.26% | -2,106.53% | -5,368.43% | -434.63% | 1.00% | -0.89% | 4.24% | -1.70% | 2.39% | 18.39% | 8.97% | 9.68% |
| Operating Income | -9.50M | -4.90M | -4.19M | -4.59M | -5.81M | -4.48M | -4.65M | -3.74M | -3.57M | -3.34M | -3.33M | -3.46M | -3.29M | -3.40M | -3.20M | -4.97M | -5.15M | -4.06M | -2.42M | -2.38M | -1.01M | -1.50M | -490.59K | -3.40M | -900.00K | -700.00K | 1.40M | 900.00K |
| Operating Income Ratio | -480.51% | -283.25% | -209.01% | -375.70% | -320.75% | -182.15% | -207.41% | -189.00% | -198.32% | -242.83% | -221.33% | -279.73% | -333.10% | -253.63% | -256.77% | -582.73% | -796.94% | -1,929.78% | -2,292.44% | -577.35% | -4.35% | -6.61% | -2.25% | -17.48% | -3.07% | -2.68% | 6.28% | 5.81% |
| Total Other Income/Expenses | -19.81M | -11.18M | -15.97M | -11.42M | -6.07M | -5.22M | -6.07M | 1.03M | -3.85M | -1.27M | -757.24K | 11.42K | 293.83K | 246.78K | 4.99K | 57.95K | 2.32M | 899.65K | 3.62M | -301.04K | -2.37M | -206.16K | -380.49K | -3.06M | -413.83K | -4.30M | 300.00K | -100.00K |
| Income Before Tax | -29.31M | -16.08M | -20.15M | -16.01M | -11.88M | -9.70M | -10.72M | -2.71M | -7.42M | -4.61M | -4.08M | -3.45M | -3.00M | -3.15M | -3.19M | -4.91M | -2.83M | -3.16M | 1.20M | -2.68M | -1.29M | -1.71M | -871.08K | -6.46M | -1.30M | -5.00M | 1.70M | 800.00K |
| Income Before Tax Ratio | -1,482.19% | -929.64% | -1,006.48% | -1,311.29% | -656.25% | -394.62% | -478.27% | -136.96% | -412.49% | -335.52% | -271.70% | -278.81% | -303.35% | -235.22% | -256.37% | -575.93% | -438.45% | -1,501.96% | 1,139.95% | -650.31% | -5.52% | -7.51% | -3.99% | -33.19% | -4.44% | -19.16% | 7.62% | 5.16% |
| Income Tax Expense | 0.00 | 747.67K | 14.45M | 8.34M | -217.17K | -1.05M | 5.86M | 4.50M | 4.15M | 1.30M | 757.24K | -2.01K | 136.60K | -23.71K | -623.26K | 0.00 | -520.21K | -745.35K | 329.97K | -941.35K | 3.43K | 2.94K | 15.68K | 1.15M | -500.00K | -600.00K | 700.00K | 300.00K |
| Net Income | -29.31M | -16.82M | -34.60M | -24.35M | -11.66M | -9.70M | -10.72M | -2.71M | -7.42M | -4.61M | -4.08M | -3.45M | -3.00M | -3.13M | -2.57M | -4.91M | -1.16M | -2.41M | 872.97K | 12.71M | -1.29M | -1.49M | 3.45M | -8.00M | -800.00K | -4.40M | 1.00M | 500.00K |
| Net Income Ratio | -1,482.19% | -972.88% | -1,728.14% | -1,994.92% | -644.25% | -394.62% | -478.27% | -136.96% | -412.49% | -335.52% | -271.70% | -278.64% | -303.35% | -233.45% | -206.31% | -575.93% | -178.93% | -1,147.52% | 827.26% | 3,080.97% | -5.53% | -6.54% | 15.80% | -41.09% | -2.73% | -16.86% | 4.48% | 3.23% |
| EPS | -1.51 | -1.52 | -5.21 | -7.37 | -5.87 | -6.34 | -9.62 | -2.97 | -10.73 | -9.70 | -10.37 | -10.19 | -13.58 | -34.93 | -33.29 | -67.11 | -16.68 | -30.21 | 18.60 | 55.80 | -5.68 | -6.70 | 16.80 | -43.80 | -5.14 | -28.36 | 6.90 | 5.10 |
| EPS Diluted | -1.51 | -1.52 | -5.21 | -7.37 | -5.87 | -6.34 | -9.62 | -2.97 | -10.73 | -9.70 | -10.37 | -10.19 | -13.58 | -34.93 | -33.29 | -67.11 | -16.68 | -30.21 | 17.70 | 55.80 | -5.68 | -6.70 | 16.80 | -43.80 | -5.14 | -28.36 | 6.30 | 4.20 |
| Weighted Avg Shares Out | 23.34M | 11.06M | 6.64M | 3.30M | 1.99M | 1.53M | 1.11M | 911.31K | 690.87K | 475.49K | 394.06K | 338.47K | 220.61K | 89.57K | 77.14K | 73.14K | 69.29K | 79.87K | 99.09K | 228.34K | 227.02K | 222.02K | 206.81K | 182.67K | 155.66K | 155.17K | 144.93K | 145.93K |
| Weighted Avg Shares Out (Dil) | 23.34M | 11.06M | 6.64M | 3.30M | 1.99M | 1.53M | 1.11M | 911.31K | 690.87K | 475.49K | 394.06K | 338.47K | 220.61K | 89.57K | 77.14K | 73.14K | 69.29K | 79.87K | 103.60K | 228.34K | 227.02K | 222.02K | 208.13K | 182.67K | 155.66K | 155.17K | 158.73K | 145.93K |
Pressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray
CANTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for...
Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET
CANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business...
Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET
SOUTH EASTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of...
Pressure BioSciences' Uncle Bud's Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”
PBIO Receives Critical Processor License for Industrial Hemp in MA . New License and Relocation to Enhanced Manufacturing Facility Allows Company to Supplement Production with West Coast Partner to Manage Anticipated Onset of Purchase Order Increases.
Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.
SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global...
Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing
CANTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for...
Pressure BioSciences, Inc. (PBIO) Acquisition of Uncle Bud's Conference Call (Transcript)
Pressure BioSciences, Inc. (PBIO) Acquisition of Uncle Bud's Conference Call (Transcript)
Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness
Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5 th Investor Call to Discuss Impact of Recent Uncle...
Pressure BioSciences Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds
SOUTH EASTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global...
Pressure BioSciences Announces Closing of Uncle Bud's Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales
SOUTH EASTON, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global...
Source: https://incomestatements.info
Category: Stock Reports